cc10
Recombinant proteinexperimental
Clinical trial activity
2 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2000 (NCT01473264)
Timeline
Indications
Mechanism of action
- UteroglobinINHIBITOR
SCGB1A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSMRS7SR55LQ ↗
Also known as
- cc10
- rhcc10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01941745 | Phase 2 | Oct 1, 2013 | Harvard University, Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii, SP ZOZ Szpital Uniwersytecki w Krakowie Oddizat Neonatologii, Therabron Therapeutics, Inc., Tufts University, University of Massachusetts |
| NCT01473264 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2000 | Clarassance, Inc., National Heart, Lung, and Blood Institute (NHLBI), Stony Brook University, University of Maryland |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarassance, Inc. | For profit | 1 | 1 | 1 | 2000 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii | Academic/Hospital | 1 | 0 | 1 | 2013 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2000 |
| SP ZOZ Szpital Uniwersytecki w Krakowie Oddizat Neonatologii | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Stony Brook University | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Therabron Therapeutics, Inc. | For profit | 1 | 0 | 1 | 2013 |
| Tufts University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2000 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2013 |
10 organizations
Page 1 / 1